|By PR Newswire||
|August 25, 2014 08:40 AM EDT||
NEW YORK, August 25, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding GlaxoSmithKline PLC (NYSE: GSK), Amicus Therapeutics, Inc. (NASDAQ: FOLD), WellPoint Inc. (NYSE: WLP), IDEXX Laboratories, Inc. (NASDAQ: IDXX) and Endo International PLC (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5933-100free.
GlaxoSmithKline PLC Research Reports
On July 31, 2014, GlaxoSmithKline PLC (GSK) and Genmab A/S announced that an Independent Data Monitoring Committee (IDMC) interim analysis of a Phase III study, PROLONG (OMB 112517), reached the predefined significance level for efficacy (p≤0.001). According to the Companies, the interim analysis demonstrated that treatment with ofatumumab (Arzerra™) met the primary endpoint of improving progression free survival (PFS). The study evaluated ofatumumab maintenance therapy versus no further treatment (observation) in patients with relapsed chronic lymphocytic leukaemia (CLL) who responded to treatment at relapse. Dr. Rafael Amado, Head of Oncology R&D, GSK said, "This interim result from the PROLONG study demonstrated that maintenance therapy with ofatumumab lowered the risk of disease progression in patients who responded to treatment at relapse. We look forward to sharing the results of the interim analysis with regulatory agencies to evaluate the potential for future regulatory filings." The full research reports on GSK are available to download free of charge at:
Amicus Therapeutics, Inc. Research Reports
On August 20, 2014, Amicus Therapeutics, Inc.'s (Amicus) stock zoomed 20.35%, on record high trading volumes, to end the trading session at $5.50, after the Company announced positive 18-month data from its second Phase 3 study (Study 012) of the oral small molecule chaperone migalastat HCl ("migalastat") in Fabry patients with amenable mutations. According to the Company, study 012 compared oral migalastat to standard-of-care enzyme replacement therapies (ERTs) for Fabry disease (Fabrazyme® and Replagal®). John F. Crowley, Chairman and CEO of Amicus Therapeutics, Inc., stated, "We believe that this multi-year study unequivocally demonstrates that a Fabry patient on ERT with an amenable mutation can switch safely and effectively from ERT to migalastat to treat their Fabry disease," He continued, "This study was resoundingly positive and met our pre-defined criteria for success in terms of the co-primary endpoints of kidney function. These results clearly show that migalastat is comparable to ERT in slowing the progression of Fabry disease and continues to demonstrate a favorable safety profile." The full research reports on Amicus are available to download free of charge at:
WellPoint Inc. Research Reports
On August 13, 2014, WellPoint Inc. (WellPoint) issued a press release stating that the Company plans to change its corporate name to Anthem, Inc. According to WellPoint, the change will enable the Company to establish improved alignment between its corporate and product brands, and better reflect its purpose and strategy to help transform health care. The Company stated that, the change will also enable WellPoint to streamline the communication of its values and the impact its family of companies are making on its members, associates, and investors. WellPoint informed that pending approval from shareholders, the change is expected to take place by the end of 2014. "As consumer engagement is heightened, we recognize that brand-an indicator of trust and a predictor of willingness to engage-is going to be of increasing importance," said Joseph Swedish, President and CEO of WellPoint." The full research reports on WellPoint are available to download free of charge at:
IDEXX Laboratories, Inc. Research Reports
On August 5, 2014, IDEXX Laboratories, Inc. (IDEXX) announced the launch of the IDEXX RealPCR™ BVDV RNA Test, thus expanding its bovine viral diarrhea virus (BVDV) portfolio and providing standardization at every level of real-time PCR testing. As per IDEXX, all components of the IDEXX RealPCR™ Modular System can be ordered separately, totally eliminating the concept of traditional real-time PCR kits. Christian Leutenegger, worldwide Head of PCR, IDEXX said, "With traditional PCR testing methods, it can be a real challenge to monitor and control contamination. The IDEXX RealPCR™ BVDV RNA Test has built-in quality controls and is supported by the IDEXX RealPCR™ Quality Control System, ensuring complete control at every level." The full research reports on IDEXX are available to download free of charge at:
Endo International PLC Research Reports
On August 6, 2014, Endo International PLC (Endo) announced that it has completed the acquisition of DAVA Pharmaceuticals, Inc., a privately-held company specializing in generic pharmaceuticals. The acquisition was valued at $575 million in cash, with additional cash consideration of up to $25 million contingent on the achievement of certain sales milestones. According to Endo, DAVA portfolio is well-positioned for continued strong financial performance with its existing commercial products and attractive near-term pipeline, and is a natural fit with Endo's U.S. generics business. Endo also raised its 2014 adjusted diluted EPS guidance to $4.00 - $4.20, versus prior range of $3.80 - $4.00, and 2014 revenue estimate to a range between $2.78 billion and $2.86 billion, from the earlier forecast of $2.72 billion to $2.80 billion. The full research reports on Endo are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
Feb. 11, 2016 07:00 PM EST Reads: 270
Feb. 11, 2016 05:15 PM EST Reads: 216
Feb. 11, 2016 05:00 PM EST Reads: 387
Feb. 11, 2016 04:30 PM EST
Feb. 11, 2016 04:15 PM EST Reads: 177
Feb. 11, 2016 04:00 PM EST
Feb. 11, 2016 03:45 PM EST Reads: 409
Feb. 11, 2016 03:00 PM EST
Feb. 11, 2016 02:45 PM EST
Feb. 11, 2016 02:45 PM EST Reads: 441
Feb. 11, 2016 01:45 PM EST
Feb. 11, 2016 01:45 PM EST
Feb. 11, 2016 01:30 PM EST Reads: 439
Feb. 11, 2016 12:00 PM EST
Feb. 11, 2016 12:00 PM EST Reads: 211